The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation.
A reform-minded and business-oriented administration under President Emmanuel Macron has already made significant progress, with foreign direct investment up by 31 percent in the past year. Life sciences have been placed at the heart of France’s new national industrial strategy, with significant healthcare reform already underway.
Furthermore, national champions such as Servier, Pierre Fabre and Ipsen are striking significant partnership deals and internationalizing rapidly, creating a mood of optimism throughout the French industry.
Other topics covered in this new report include France’s burgeoning medtech sector, the struggles facing generics companies implanted in France and why many are moving towards biosimilars, and a renaissance in French manufacturing and its C(D)MOs.
We also take a look at some of the industry’s hottest trends, including the intersection between artificial intelligence and healthcare and the French firms pushing forward the frontiers of cell and gene therapy and CAR-T.
The French healthcare and life sciences industries are – without doubt – undergoing rapid and potentially profound transformation. This report offers exclusive executive insight into a country looking to regain its place at the top table of global innovation.
